ReShape Lifesciences Inc. - FORM 8-K - EX-99.1 - EXHIBIT 99.1 - July 30, 2020

Attached files

file filename
8-K - 8-K - ReShape Lifesciences Inc.oblnq2-20earnings8xk.htm



Obalon Announces Second Quarter 2020 Financial Results
SAN DIEGO, CA July 30, 2020 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced its financial results for the second quarter ended June 30, 2020.
Financial results for the second quarter of 2020
Revenue for the second quarter of 2020 was $0.7 million, compared to $0.4 million for the second quarter of 2019, primarily due to reversals of revenue reserves as a result of suspending business operations at the company-branded retail treatment centers. Net loss for the second quarter of 2020 was $4.2 million, compared to $6.8 million for the second quarter of 2019. Net loss per share for the second quarter of 2020 was $0.54, compared to $2.52 for the second quarter of 2019.
Cost of revenue was $0.4 million for the second quarter of 2020, down from $0.7 million for the second quarter of 2019. Gross profit for the second quarter of 2020 was $0.3 million, compared to a gross deficit of $0.3 million for the second quarter of 2019.
Research and Development expense for the second quarter of 2020 totaled $0.8 million, down from $1.8 million for the second quarter of 2019. Selling, General and Administrative expense decreased to $2.4 million for the second quarter of 2020, compared to $4.3 million for the second quarter of 2019.
The Company recognized $1.3 million impairment expense and other charges related to its inventory and long-lived assets during the second quarter of 2020, as a result in the Company's shift in business strategy away from the retail treatment centers to reimbursement.
Operating loss for the second quarter of 2020 was $4.2 million, down from a loss of $6.4 million for the second quarter of 2019.
As of June 30, 2020, the Company had cash and cash equivalents of $6.8 million and $0.4 million of debt related to its Payroll Protection Program loan. The Company intends to continue exploring the potential for third-party reimbursement for the Obalon Balloon System, as well as

1


exploring and evaluating financial alternatives to help meet its capital needs and strategic alternatives that might enhance stockholder value. There is no assurance that any financial or strategic alternative will be identified. If the Company is not able to raise additional capital to meet its needs or to identify a strategic alternative in the best interest of stockholders, it will have to discontinue all operations and may be required to declare bankruptcy or dissolve.

About Obalon Therapeutics, Inc.
Obalon Therapeutics, Inc. (NASDAQ:OBLN) is a San Diego-based company focused on developing and commercializing novel technologies for weight loss.


Cautionary Statement Regarding Forward Looking Statements
This press release contains forward-looking statements that are not purely historical regarding Obalon’s or its management’s intentions, beliefs, expectations and strategies for the future, including those related to new products and their potential benefits. All forward-looking statements and reasons why results might differ included in this press release are made as of the date of this release, based on information currently available to Obalon, deal with future events, are subject to various risks and uncertainties, and actual results could differ materially from those anticipated in those forward looking statements. The risks and uncertainties that may cause actual results to differ materially from Obalon’s current expectations are more fully described in Obalon’s annual report on Form 10-K for the period ended December 31, 2019, periodic reports on Form 10-Q for the period ended June 30, 2020 and March 31, 2020 and its other reports, each as filed with the Securities and Exchange Commission. Except as required by law, Obalon assumes no obligation to update any such forward-looking statement after the date of this report or to conform these forward-looking statements to actual results.


2




OBALON THERAPEUTICS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(unaudited)
(in thousands, except shares and per share data)

 
Three Months Ended June 30,
 
Six Months Ended June 30,
 
2020
 
2019
 
2020
 
2019
 
 
 
 
 
 
 
 
 
 
Revenue
$
703

 
$
386

 
$
1,483

 
$
2,161

Cost of revenue
423

 
679

 
964

 
1,911

Gross profit (deficit)
280

 
(293
)
 
519

 
250

Operating expenses:
 
 
 
 
 

 
 

Research and development
765

 
1,788

 
2,022

 
4,227

Selling, general and administrative
2,362

 
4,332

 
6,255

 
10,536

Asset impairment and other charges
1,310

 
—

 
1,310

 
—

Total operating expenses
4,437

 
6,120

 
9,587

 
14,763

Loss from operations
(4,157
)
 
(6,413
)
 
(9,068
)
 
(14,513
)
Interest (expense) income, net
(5
)
 
(295
)
 
30

 
(485
)
Other expense, net
(26
)
 
(59
)
 
(411
)
 
(59
)
Net loss and comprehensive loss
$
(4,188
)
 
$
(6,767
)
 
$
(9,449
)
 
$
(15,057
)
Net loss per share, basic and diluted
$
(0.54
)
 
$
(2.52
)
 
$
(1.22
)
 
$
(6.02
)
Weighted-average common shares outstanding, basic and diluted
7,728,624

 
2,687,829

 
7,726,915

 
2,500,619





















3


OBALON THERAPEUTICS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands, except shares and par value data)
 
June 30, 2020
 
December 31, 2019
Assets
(unaudited)
 
 
Current assets:
 

 
 

Cash and cash equivalents
$
6,804

 
$
14,055

Accounts receivable, net
—

 
285

Inventory
—

 
1,936

Other current assets
3,971

 
1,959

Total current assets
10,775

 
18,235

Property and equipment, net
1,055

 
1,081

Lease right-of-use assets
748

 
1,077

Other long-term assets
1,295

 
—

Total assets
$
13,873

 
$
20,393

Liabilities and Stockholders’ Equity
 

 
 

Current liabilities:
 

 
 

Accounts payable
$
1,054

 
$
648

Accrued compensation
240

 
820

Deferred revenue
123

 
424

Other current liabilities
3,603

 
1,524

Current portion of lease liabilities
579

 
561

Total current liabilities
5,599

 
3,977

Lease liabilities long-term
666

 
567

Long-term debt
430

 
—

Total long-term liabilities
1,096

 
567

Total liabilities
6,695

 
4,544

Commitments and contingencies
 
 
 
Stockholders’ equity:
 

 
 

Common stock, $0.001 par value; 100,000,000 shares authorized as of June 30, 2020 and December 31, 2019; 7,731,633 and 7,724,100 shares issued and outstanding as of June 30, 2020 and December 31, 2019, respectively
8

 
8

Additional paid-in capital
189,049

 
188,271

Accumulated deficit
(181,879
)
 
(172,430
)
Total stockholders’ equity
7,178

 
15,849

Total liabilities and stockholders’ equity
$
13,873

 
$
20,393















4


OBALON THERAPEUTICS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(unaudited)
(in thousands)
 
Six Months Ended June 30,
 
2020
 
2019
 
 
Operating activities:
 

 
 

Net loss
$
(9,449
)
 
$
(15,057
)
Adjustments to reconcile net loss to net cash used in operating activities:
 
 
 
Depreciation
187

 
256

Stock-based compensation
762

 
1,641

Loss on disposal of fixed assets
—

 
95

Amortization of right-of-use assets
239

 
186

Accretion of investment discount, net
—

 
(2
)
Amortization of debt discount
—

 
70

Impairment of long-lived assets and other charges
1,257

 
—

Impairment of inventory
53

 
—

Change in operating assets and liabilities:
 
 
 
Accounts receivable, net
285

 
423

Inventory
(524
)
 
(157
)
Other current assets
(1,845
)
 
1,760

Accounts payable
405

 
(191
)
Accrued compensation
(564
)
 
(2,712
)
Deferred revenue
(302
)
 
(32
)
Lease liabilities, net
(147
)
 
(136
)
Other current and long term liabilities
2,079

 
(142
)
Net cash used in operating activities
(7,564
)
 
(13,998
)
Investing activities:
 

 
 

Maturities of short-term investments
—

 
2,550

Purchase of property and equipment
(117
)
 
(20
)
Net cash (used in) provided by investing activities
(117
)
 
2,530

Financing activities:
 

 
 

Proceeds from long-term loan
430

 
10,000

Payment on long-term loan
—

 
(15,000
)
Proceeds from issuance of common stock, net of issuance costs
—

 
8,793

Proceeds from sale of common stock upon exercise of stock options
—

 
1

Net cash provided by financing activities
430

 
3,794

Net decrease in cash and cash equivalents
(7,251
)
 
(7,674
)
Cash and cash equivalents at beginning of period
14,055

 
21,187

Cash and cash equivalents at end of period
$
6,804

 
$
13,513

Supplemental cash flow information:
 

 
 

Interest paid
$
—

 
$
563

Unpaid issuance costs
$
—

 
$
377



5

ReShape Lifesciences Inc. Reports